Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: Results of a prospective study

Annals of the Rheumatic Diseases

Volumn 78, Issue 2, 2019, Pages 171-178

  Takeuchi, Tsutomu ^a   Genovese, Mark C ^b   Haraoui, Boulos ^c   Li, Zhanguo ^d   Xie, Li ^e   Klar, Rena ^f   Pinto Correia, Ana ^e   Otawa, Susan ^e   Lopez Romero, Pedro ^e   De La Torre, Inmaculada ^e   Macias, William ^e   Rooney, Terence P ^e   Smolen, Josef S ^g  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^e ELI LILLY AND COMPANY   (United States)

^f IQVIA   (United States)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

disease activity; DMARDs (biologic); DMARDs (synthetic); rheumatoid arthritis

Indexed keywords

BARICITINIB; PLACEBO; ANTIRHEUMATIC AGENT; AZETIDINE DERIVATIVE; SULFONAMIDE;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CONTROL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT DURATION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CONTROLLED STUDY; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; PROCEDURES; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AZETIDINES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; SULFONAMIDES; TREATMENT OUTCOME;

EID: 85053145147     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2018-213271     Document Type: Article

References (17)

1. S molen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016;75:3-15.
2. S ingh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 2016;68:1-26.
3. S molen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960-77.
4. Tanaka Y, Hirata S, Saleem B. Discontinuation of biologics in patients with rheumatoid arthritis. Clin Exp Rheumatol 2013;31(Suppl 78):S22-7.
5. Tanaka Y, Hirata S, Kubo S, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis 2015;74:389-95.
6. A llaart CF, Lems WF, Huizinga TW. The BeSt way of withdrawing biologic agents. Clin Exp Rheumatol 2013;31(4 Suppl 78):S14-18.
7. S molen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013;381:918-29.
8. Takeuchi T, Matsubara T, Ohta S, et al. Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan. Rheumatology 2015;54:683-91.
9. ten Wolde S, Hermans J, Breedveld FC, et al. Effect of resumption of second line drugs in patients with rheumatoid arthritis that flared up after treatment discontinuation. Ann Rheum Dis 1997;56:235-9.
10. O'Shea JJ, Schwartz DM, Villarino AV, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med 2015;66:311-28.
11. Dougados M, van der Heijde D, Chen YC, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 2017;76:88-95.
12. Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 2017;376:652-62.
13. Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 2016;374:1243-52.
14. Fleischmann R, Schiff M, van der Heijde D, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior diseasemodifying antirheumatic drug treatment. Arthritis Rheumatol 2017;69:506-17.
15. Keystone EC, Taylor PC, Drescher E, et al. Safety and efficacy of baricitinib at24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis 2015;74:333-40.
16. Tanaka Y, Emoto K, Cai Z, et al. Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomized placebo-controlled study. J Rheumatol 2016;43:504-11.
17. Zhang X, Chua L, Ernest C, et al. Dose/Exposure-response modeling to support dosing recommendation for phase III development of baricitinib in patients with rheumatoid arthritis. CPT Pharmacometrics Syst Pharmacol 2017;6:804-13.